Gain Therapeutics Stock (NASDAQ:GANX)
Previous Close
$1.47
52W Range
$0.89 - $5.33
50D Avg
$1.17
200D Avg
$2.69
Market Cap
$37.41M
Avg Vol (3M)
$423.01K
Beta
0.35
Div Yield
-
GANX Company Profile
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
GANX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CUE | Cue Biopharma, Inc. |
| CYT | Cyteir Therapeutics, Inc. |
| INBX | Inhibrx, Inc. |
| CSBR | Champions Oncology, Inc. |
| BIVI | BioVie Inc. |
| LTRN | Lantern Pharma Inc. |
| MNOV | MediciNova, Inc. |
| INAB | IN8bio, Inc. |
| NAMS | NewAmsterdam Pharma Company N.V. |
| TFFP | TFF Pharmaceuticals, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| MOLN | Molecular Partners AG |
| LIFE | aTyr Pharma, Inc. |
| CELC | Celcuity Inc. |
| MACK | Merrimack Pharmaceuticals, Inc. |
| ELVN | Enliven Therapeutics, Inc. |
| ELYM | Eliem Therapeutics, Inc. |